Protalix BioTherapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio47.2115.62
Forward P/E3.9460.89
P/S Ratio2.591.981.460.991.88
P/B Ratio3.203.87-6.52-6.28-4.38
Price/Tangible Book3.203.87
Price/FCF18.73
Price/OCF15.96
Enterprise Value Ratios
EV/Revenue2.191.751.720.682.24
EV/EBITDA22.359.8635.08
EV/EBIT29.8010.9851.93
EV/FCF15.79
Profitability & Returns
Return on Equity (ROE)0.08%0.72%
Return on Assets (ROA)0.03%0.09%-0.13%-0.18%0.03%
Return on Invested Capital (ROIC)0.19%1.27%
Return on Capital Employed (ROCE)0.08%0.27%-0.56%-0.51%-0.15%
Leverage & Solvency Ratios
Debt/Equity0.130.78-3.15-5.54-2.38
Debt/EBITDA0.812.0011.94
Debt/FCF0.75
Liquidity Ratios
Current Ratio2.351.541.381.860.64
Quick Ratio1.491.100.841.290.48
Efficiency Ratios
Asset Turnover0.680.930.740.541.11
Inventory Turnover1.211.281.131.051.02
Yield & Distribution Ratios
Earnings Yield0.02%0.06%-0.21%-0.73%-0.06%
FCF Yield0.05%-0.02%-0.37%-0.31%-0.23%
Buyback Yield0.02%-0.70%-0.10%-0.51%-0.96%